Working to Eradicate Gynecologic Cancers

Poster Session B

Sunday, March 29, 2015: 7:00 AM-4:00 PM
Salon C-D (Hilton Chicago)
Description:
7:00 AM
340
AKT survival signaling and phospho-AKT expression are associated with triple negative breast cancer development and clinical outcome
D. Marchion1, R. Ismail-Khan1, F. Abbasi1, B. Boac2, Y. Xiong1, C. McClung2, E. Al Sawah3, S. H. Bush3, A. Hakam1 and J. M. Lancaster1
1H. Lee Moffitt Cancer Center, Tampa, FL, 2H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, 3University of South Florida College of Medicine, Tampa, FL
 
7:00 AM
341
Optimal margins: a retrospective analysis of surgical margins in patients who underwent breast-conserving surgery prior to the release of the 2014 SSO/ASTRO consensus guidelines
L. K. Berry1, K. L. Wang1, S. L. Galvin1, A. B. Parlier1, C. B. Harkness2,3, A. S. Case2,3 and D. J. Hetzel2,3
1Mountain Area Health and Education Center, Asheville, NC, 2Hope Women's Cancer Centers - Mission Cancer Care, Mission Health, Asheville, NC, 3University of North Carolina School of Medicine, Chapel Hill, NC
 
7:00 AM
342
Different patterns of tumor size and serum SCC antigen level for prediction of parametrial invasion in pre- and post-menopausal patients with FIGO stage IB cervical cancer
T. W. Kong1, S. J. Chang1, J. H. Son1, S. W. Kang2, J. Paek1 and H. S. Ryu2
1Ajou University Hospital, Suwon, South Korea, 2Ajou University School of Medicine, Suwon, South Korea
 
7:00 AM
343
What is the impact of distance from a comprehensive cancer center on survival in patients with cervical cancer?
E. E. Landers, E. D. Thomas, D. Barrington, J. D. Boone, J. M. Straughn Jr., G. McGwin and C. A. Leath III
University of Alabama at Birmingham, Birmingham, AL
 
7:00 AM
344
Morbidity of triple modality therapy in the management of early stage cervical cancer
S. K. Park1, M. W. Amneus2, A. E. Axtell3, B. Hakimian4, A. J. Li5, R. S. Leuchter5, B. Y. Karlan5, B. J. Rimel5, C. Walsh5, C. H. Holschneider6 and I. Cass5
1UCLA/Cedars-Sinai, Torrance, CA, 2Olive View-UCLA Medical Center, Sylmar, CA, 3Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, 4Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA, 5Cedars-Sinai Medical Center, Los Angeles, CA, 6David Geffen School of Medicine at UCLA, Sylmar, CA
 
7:00 AM
345
Comparison of FLT- and FDG-PET in gynecological cancers
L. P. Cho1,2, C. Kim1,2 and A. Viswanathan1,2
1Brigham and Women's Hospital, Boston, MA, 2Dana Farber Cancer Institute, Boston, MA
 
7:00 AM
346
Outpatient laparoscopic radical hysterectomy
L. M. Echeverri1, G. J. Rendón1, R. Pareja1, F. E. Echeverri2, M. A. Madariaga3 and P. T. Ramirez4
1Instituto de Cancerología - Las Américas, Medellín, Colombia, 2Clínica Las Américas, Medellín, Colombia, 3Hospital de San José, Bogotá, Colombia, 4The University of Texas MD Anderson Cancer Center, Houston, TX
 
7:00 AM
347
Microarray analysis of vascular endothelial growth factor (VEGF)-dependent angiogenic biomarkers in squamous cell carcinoma (SCCA) and adenocarcinoma (AC) of the cervix
R. Feldman1, Z. Gatalica1, S. K. Reddy1 and K. S. Tewari2
1Caris Life Sciences, Irving, TX, 2UC Irvine Medical Center, Orange, CA
 
7:00 AM
348
Paving the road to personalized medicine in cervical cancer: theranostic biomarker evaluation in a 592-specimen library
R. Feldman1, Z. Gatalica1, S. K. Reddy1 and K. S. Tewari2
1Caris Life Sciences, Irving, TX, 2UC Irvine Medical Center, Orange, CA
 
7:00 AM
349
Immediate radical trachelectomy versus neoadjuvant chemotherapy followed by radical trachelectomy for patients with stage IB1 cervical cancer with tumors 2 cm or larger: a literature review and analysis of oncological and obstetrical outcomes
R. Pareja1, G. J. Rendón1, L. M. Echeverri1, S. M. Lucchini Sr.2, M. A. Madariaga3, M. Araujo4 and P. T. Ramirez5
1Instituto de Cancerología - Las Américas, Medellín, Colombia, 2Hospital Nacional de Clinicas, Cordoba, Argentina, 3Hospital de San José, Bogotá, Colombia, 4centro medico docente la trinidad, caracas, Venezuela, 5The University of Texas MD Anderson Cancer Center, Houston, TX
 
7:00 AM
350
Cone biopsy can avoid overtreatment in IB cervical cancer patients
R. Ribeiro1, B. R. Bereza1, M. A. Luz1, C. D. N. Nadai2 and J. C. Linhares1
1Erasto Gaertner Hospital, Curitiba, Brazil, 2A. C. Camargo Cancer Center, São Paulo, Brazil
 
7:00 AM
351
The use of electronic health record-based tools to improve cervical cancer screening compliance in a large community-based health care organization
C. Thompson1, A. B. Gardner1, D. S. Kapp2 and J. K. Chan3
1Palo Alto Medical Foundation Research Institute, Palo Alto, CA, 2Stanford University, Stanford, CA, 3California Pacific & Palo Alto Medical Foundation / Sutter Research Institute, San Francisco, CA
 
7:00 AM
352
Impact of positive peritoneal cytology on prognosis in patients with cervical cancer: a meta-analysis
S. Yoon, S. H. Shim, S. J. Lee and S. N. Kim
Konkuk University School of Medicine, Seoul, South Korea
 
7:00 AM
353
Cervical cancer epidemiology in former Soviet Union immigrants to Israel: a step towards solving the enigma
Y. Raz1, D. Grisaru2, L. Boker-Keinan3,4, D. Cohen5 and S. Goren5
1Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 2Tel-Aviv University, Tel-Aviv, Israel, 3Gertner institute,Ministry of health, sheba medical center, Tel Hashomer, Israel, 4Haifa University, Heifa, Israel, 5Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
 
7:00 AM
354
Surveillance for recurrent cervical cancer: 10 years of Pap smears for cervical cancer survivors and not a single life saved by cytology
E. Saks1, O. Moskowitz2 and L. Duska2
1University of Virginia Medical Center, Charlottesville, VA, 2University of Virginia School of Medicine, Charlottesville, VA
 
7:00 AM
355
Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study
S. E. Waggoner1, J. Java2, B. J. Monk3, H. Michael4, R. T. Penson5, M. M. Leitao6, R. L. Coleman7, R. S. Mannel8, A. Oaknin9 and K. S. Tewari10
1University Hospitals Case Medical Center, Cleveland, OH, 2Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, 3University of Arizona Cancer Center, Phoenix, AZ, 4Indiana University School of Medicine, Indianapolis, IN, 5Massachusetts General Hospital/Harvard University, Boston, MA, 6Memorial Sloan Kettering Cancer Center, New York, NY, 7The University of Texas MD Anderson Cancer Center, Houston, TX, 8University of Oklahoma Health Sciences Center, Oklahoma City, OK, 9GEICO (Grupo Espanol de Investigacion en Cancer de Ovario), Barcelona, Spain, 10UC Irvine Medical Center, Orange, CA
 
7:00 AM
356
Neratinib, an irreversible pan-ErbB receptor inhibitor, is highly effective against primary cervical cancer cell lines harboring HER2/neu gene mutations
S. Lopez1, S. Bellone2, J. D. Black2, C. L. Schwab2, D. P. English2, C. Terranova1, P. E. Schwartz2, T. J. Rutherford2, R. Angioli1 and A. Santin2
1University Campus Bio-Medico of Rome, Rome, Italy, 2Yale University School of Medicine, New Haven, CT
 
7:00 AM
357
Evaluation for health care disparities in Hispanic and Non-Hispanic Whites with cervical cancer using National Cancer Database
E. Chalas1, V. Rojas1, J. A. Villella1, E. A. Jimenez1, K. C. Chan1, M. Fazzari1, H. Toskos2 and J. Rosario-Garcia3
1Winthrop University Hospital, Mineola, NY, 2Stony Brook University, Stony Brook, NY, 3Stony Brook University Medical Center, Stony Brook, NY
 
7:00 AM
358
Surgical, pathologic and survival outcomes of patients undergoing open, laparoscopic or robotic radical hysterectomy for invasive cervical cancer
V. Andikyan, R. Carroll, J. Fields, H. F. Gretz III, L. T. Chuang, P. Dottino and K. Zakashansky
Icahn School of Medicine at Mount Sinai, New York, NY
 
7:00 AM
359
Does use of uterine manipulator alter the rate of lymphovascular space invasion in patients with invasive cervical cancer undergoing radical hysterectomy?
V. Andikyan, R. Carroll, J. Fields, P. Dottino and K. Zakashansky
Icahn School of Medicine at Mount Sinai, New York, NY
 
7:00 AM
360
Health care delivery failure for cervical cancer screening in a high risk population
K. M. Wishall1, K. A. Brandt1, M. Morin2, M. L. Podolsky2 and S. D. Richard1
1Hahnemann University Hospital/Drexel University College of Medicine, Philadelphia, PA, 2Drexel University College of Medicine, Philadelphia, PA
 
7:00 AM
361
The BAD apoptotic pathway: a cervical cancer therapeutic target associated with disease development, therapeutic response and patient survival
S. H. Bush1, D. Marchion2, Y. Xiong2, F. Abbasi2, A. Berry1, H. S. Chon2, M. M. K. Shahzad2, S. M. Apte2, R. M. Wenham2, P. Judson1 and J. M. Lancaster2
1H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, 2H. Lee Moffitt Cancer Center, Tampa, FL
 
7:00 AM
362
Radical abdominal and robotic hysterectomy: perioperative and oncologic outcome of 175 cases
E. M. Salom1, M. A. Penalver2, L. E. Mendez3, J. Atlass4, Y. Mendez4, L. Sagmiester4, C. Gauthreaux4, M. Gaffley4 and K. Musgrove4
1Florida International University, Miami Springs, FL, 2Florida International University, Herbert Wertheim College of Medicine, Coral Gables, FL, 3South Florida Gynecologic Oncology, Coral Gables, FL, 4Florida International University College of Medicine, University Park, FL
 
7:00 AM
363
Investigation of the timing of neoadjuvant chemotherapy on survival in advanced stage ovarian cancer
M. E. Buechel, H. Mahdi, P. G. Rose and C. Michener
Cleveland Clinic, Cleveland, OH
 
7:00 AM
364
Outpatient rapid desensitization for gynecologic oncology patients with moderate to severe hypersensitivity reactions to platinums
Q. Li1, D. E. Cohn1, A. G. Rhoades2, F. J. Backes1, L. J. Copeland1, J. M. Fowler1, R. Salani1 and D. M. O'Malley1
1The Ohio State University, James Cancer Hospital, Columbus, OH, 2University of Cincinnati Academic Health Center, Cincinnati, OH
 
7:00 AM
365
Long term follow-up of a phase II trial of multimodal therapy given in the ‘sandwich’ method for stage III, IV, and recurrent endometrial cancer
M. A. Geller1, R. Isaksson Vogel1, J. Burgart2 and K. Dusenbery2
1University of Minnesota, Minneapolis, MN, 2University of Minnesota Cancer Center, Minneapolis, MN
 
7:00 AM
366
Minimally invasive interval debulking surgery in AEOC: preliminary results from the MISSION trial
S. Gueli Alletti1, F. Fanfani1, C. Bottoni2, B. Costantini1, V. Gallotta2, G. Vizzielli2, M. Petrillo2, G. Scambia1 and A. Fagotti3
1Catholic University Sacred Heart of Rome, Rome, Italy, 2Catholic University of the Sacred Heart, Milan, Italy, 3St. Maria Hospital, University of Perugia, Terni, Italy
 
7:00 AM
367
Phase I study of intravenous (IV) oxaliplatin and intraperitoneal (IP) docetaxel in recurrent ovarian and primary peritoneal cancer
S. E. Taylor1, R. Li2, J. S. Petschauer3, H. D. Donovan2, W. C. Zamboni3, R. P. Edwards1 and K. K. Zorn4
1Magee-Womens Hospital of UPMC, Pittsburgh, PA, 2University of Pittsburgh, Pittsburgh, PA, 3University of North Carolina at Chapel Hill, Chapel Hill, NC, 4University of Arkansas for Medical Sciences, Little Rock, AR
 
7:00 AM
368
Intra-operative handoffs and postoperative complications among gynecologic oncology patients
K. M. Doll1,2, C. L. Crane1, J. A. Lavery3, A. C. Snavely1 and P. A. Gehrig1,2
1University of North Carolina at Chapel Hill, Chapel Hill, NC, 2University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, 3Columbia University College of Physicians and Surgeons, New York, NY
 
7:00 AM
369
Cancer-related fertility education in women at a public rural institution
H. E. Spencer and L. Duska
University of Virginia School of Medicine, Charlottesville, VA
 
7:00 AM
370
Gemcitabine and docetaxel compared to radiation or other chemotherapy regimens as adjuvant treatment for stage I-IV uterine leiomyosarcoma
D. R. Roque1, K. Taylor2, M. Palisoul3, W. Z. Wysham1, B. Milam1, K. M. Robison2, P. A. Gehrig1, C. Raker2 and K. H. Kim1
1University of North Carolina at Chapel Hill, Chapel Hill, NC, 2Women & Infants Hospital, Brown University, Providence, RI, 3Brown University OBGYN, Providence, RI
 
7:00 AM
371
Survey of current practice patterns in the treatment of early stage endometrial cancer among SGO members
E. B. Pereira1, B. De1, V. Kolev2, K. Zakashansky1, S. Green1, P. Dottino1 and V. Gupta3
1Icahn School of Medicine at Mount Sinai, New York, NY, 2Beth Israel Medical Center, New York, NY, 3Mount Sinai Medical Center, New York, NY
 
7:00 AM
372
Structured patient reminder systems and HPV vaccine completion rates: a quality improvement initiative
A. Wainwright1, B. Brimmage2, M. S. Barratt1, S. Robazetti1, M. P. Gomez1, L. M. Ramondetta3, K. M. Schmeler3 and L. A. Meyer3
1The University of Texas Medical School at Houston, Houston, TX, 2University of North Carolina at Chapel Hill, Chapel Hill, NC, 3The University of Texas MD Anderson Cancer Center, Houston, TX
 
7:00 AM
373
Post-operative enteral immunonutrition for gynecologic oncology patients undergoing laparotomy decreases wound complications
J. S. Chapman1, E. R. Roddy2, G. Westhoff1, E. J. Simons1, R. A. Brooks1, S. M. Ueda1 and L. M. Chen1
1UCSF Helen Diller Comprehensive Cancer Center, San Francisco, CA, 2University of California, San Francisco, San Francisco, CA
 
7:00 AM
374
Hiding in plain sight: the prevalence of obstructive sleep apnea in gynecologic oncology patients
C. Peterson, E. E. Medlin, S. Miakowski, Y. Y. Gong, R. Spencer, D. M. Kushner, S. L. Rose, L. M. Barroilhet, E. M. Hartenbach, A. N. Al-Niaimi and L. W. Rice
University of Wisconsin School of Medicine and Public Health, Madison, WI
 
7:00 AM
375
Concomitant anal and cervical high-risk HPV genotyping in women with and without lower genital tract dysplasia or neoplasia
A. J. Bregar1, B. Cronin1, C. Luis1, P. A. DiSilvestro2, C. Raker2, M. Clark3 and K. M. Robison2
1Brown University, Women and Infants Hospital, Providence, RI, 2Women and Infants Hospital, Brown University, Providence, RI, 3Brown University, Providence, RI
 
7:00 AM
376
Departmental mortality review and present on admission indicator reporting improves observed-to-expected mortality ratios
J. D. Boone, E. D. Thomas, J. M. Straughn Jr. and W. K. Huh
University of Alabama at Birmingham, Birmingham, AL
 
7:00 AM
377
Conservative management of endometrial hyperplasia/carcinoma with Levonorgestrel Intrauterine System may be less effective in patients with morbid obesity
A. Graul1, A. F. Haggerty2, H. Reed3 and S. H. Kim2
1Hospital of the University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania, Philadelphia, PA, 3Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
 
7:00 AM
378
Does performing fewer pelvic lymphadenectomies for low-intermediate risk type 1 endometrial cancer and performing secondary staging surgeries with para-aortic lymphadenectomy in lymph vascular invasion impact patients?
Y. Borghesi, F. Narducci, L. Bresson, E. Tresch, S. Cousin, A. Cordoba, B. Merlot and E. Leblanc
Centre Oscar Lambret, Lille, France
 
7:00 AM
379
Weight change after participation in a technology-based weight loss intervention for endometrial cancer survivors with obesity
A. F. Haggerty1, G. Raggio2, J. Spitzer1, D. B. Sarwer1, E. M. Ko3, C. Chu4 and K. Allison1
1University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania Health System, Philadelphia, PA, 3University of Pennsylvania, Penn Medicine, Philadelphia, PA, 4Fox Chase Cancer Center, Philadelphia, PA
 
7:00 AM
380
Is Indocyanine green (ICG) the best tracer for sentinel lymph node (SLN) mapping in early-stage cervical and endometrial cancer?
M. Plante1, O. Touhami2, X. B. Trinh2, J. Grégoire2, A. Sebastianelli2 and M. C. Renaud2
1Laval University, L'Hotel-Dieu de Quebec, Quebec City, QC, Canada, 2L'Hotel-Dieu de Quebec, Québec, QC, Canada
 
7:00 AM
381
Molecular profile of uterine papillary serous carcinoma compared to ovarian serous carcinoma: is it the same disease at different site?
H. Mahdi1, J. Xiu2, S. K. Reddy2 and R. DeBernardo1
1Cleveland Clinic, Cleveland, OH, 2Caris Life Sciences, Irving, TX
 
7:00 AM
382
Under-utilization of minimally invasive surgery in the management of endometrial cancer: a Healthcare Cost and Utilization Project-National Inpatient Sample study (HCUP-NIS)
A. Nickles Fader1, R. Matsuno2, A. K. Sinno3, E. J. Tanner III3, K. C. Long3, R. E. Bristow4 and S. C. Dowdy5
1Johns Hopkins Medical Institutions, Baltimore, MD, 2University of California San Diego Medical Group, La Jolla, CA, 3Johns Hopkins Hospital, Baltimore, MD, 4University of California, Irvine, Irvine, CA, 5Mayo Clinic, Rochester, MN
 
7:00 AM
383
Distinct molecular landscapes between endometrioid and non-endometrioid uterine carcinoma
N. L. Jones1, J. Xiu2, S. K. Reddy2, A. I. Tergas1, W. M. Burke1, J. D. Wright1 and J. Y. Hou1
1NYP/Columbia University Medical Center, New York, NY, 2Caris Life Sciences, Irving, TX
 
7:00 AM
384
Factors associated with successful bilateral sentinel lymph node mapping in endometrial cancer
A. K. Sinno, A. Nickles Fader, K. C. Long, K. Levinson, R. L. Stone and E. J. Tanner III
Johns Hopkins Hospital, Baltimore, MD
 
7:00 AM
385
Differences in BMI and physical activity in Whites vs. Asians in California in association with type I uterine cancer
T. Tsuei1, K. Blansit2, A. B. Gardner2, R. A. Brooks1, S. M. Ueda1, D. S. Kapp3 and J. K. Chan4
1UCSF Helen Diller Comprehensive Cancer Center, San Francisco, CA, 2Palo Alto Medical Foundation Research Institute, Palo Alto, CA, 3Stanford University, Stanford, CA, 4California Pacific & Palo Alto Medical Foundation / Sutter Research Institute, San Francisco, CA
 
7:00 AM
386
The feasibility and effectiveness of a 12-week social cognitive theory-based physical activity intervention for obese, ethnically diverse endometrial cancer survivors
A. Rossi1,2,3, C. E. Garber3, M. Ortiz4, G. Kaur5, A. Moadel5, G. L. Goldberg5, Y. S. Kuo5, S. Viswanathan6 and N. S. Nevadunsky5
1Montefiore Medical Center, New York, NY, 2Long Island University - Brooklyn, Brooklyn, NY, 3Teachers College Columbia University, New York, NY, 4Brooklyn College, Brooklyn, NY, 5Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, 6Albert Einstein College of Medicine, Bronx, NY
 
7:00 AM
387
Awareness of the association between obesity and perioperative risk among newly diagnosed endometrial cancer patients
L. M. Kuroki1, T. Benn2, J. Dukes3, P. H. Thaker1, A. R. Hagemann1, M. A. Powell1, D. G. Mutch1, L. S. Massad1 and I. Zighelboim4
1Washington University School of Medicine, St. Louis, MO, 2FemCare Ob-Gyn, Miami, FL, 3Washington University School of Medicine, St Louis, MO, 4St. Luke's Cancer Care Associates, Bethlehem, PA
 
7:00 AM
388
The impact of diabetes and metformin on clinical outcomes is negligible in risk-adjusted endometrial cancer cohorts
M. AlHilli, J. N. Bakkum-Gamez, A. Mariani, V. Shridhar, B. A. Cliby, M. McGree, A. L. Weaver, S. C. Dowdy and K. C. Podratz
Mayo Clinic, Rochester, MN
 
7:00 AM
389
Cancer of the uterus and treatment of incontinence (CUTI)
K. M. Robison1, E. Lokich2, P. A. DiSilvestro1, S. Raman2, C. Luis2, C. Raker1, M. Clark3 and K. Wohlrab2
1Women and Infants Hospital, Brown University, Providence, RI, 2Brown University, Women and Infants Hospital, Providence, RI, 3Brown University, Providence, RI
 
7:00 AM
390
Magnetic resonance imaging utility to predict myometrial invasion in endometrial carcinoma: 10 years experience of single institution in Argentina
J. Di Guilmi Sr.
Hospital Britanico De Buenos Aires, Buenos Aires, Argentina
 
7:00 AM
391
Is endometrial cancer different in Asian American women?
L. E. Dockery1, N. A. Conn2, W. C. Strohsnitter1, Y. B. Kim3 and E. Chapman-Davis4
1Tufts New England Medical Center, Boston, MA, 2Tufts University School of Medicine, Boston, MA, 3Tufts Medical Center, Boston, MA, 4Tufts University School of Medicine/ Tufts Medical Center, Boston, MA
 
7:00 AM
392
Next-generation sequencing demonstrates genomic signature of resistance patterns following phosphatidylinositol 3-kinase (PI3K) inhibition
J. A. Rauh-Hain1, M. Kim2, L. Zhang2, R. Foster2, B. R. Rueda2, M. Bhasin3 and W. B. Growdon1
1Massachusetts General Hospital/Harvard University, Boston, MA, 2Massachusetts General Hospital, Boston, MA, 3Beth Israel Deaconess Medical Center, Boston, MA
 
7:00 AM
393
Does obesity affect pathologic agreement of initial and final tumor grade of disease in endometrial cancer patients?
L. R. Daily, J. D. Boone, H. C. Machemehl, E. D. Thomas, G. McGwin, M. Straughn and C. A. Leath III
University of Alabama at Birmingham, Birmingham, AL
 
7:00 AM
394
Morcellation and the incidence of occult malignancy: a dual-institution review
T. Picerno1, M. Zuber2, A. Gonzalez Rios3, N. P. Taylor4, M. Hoffman1 and M. E. Borowsky5
1Christiana Care Health System, Newark, DE, 2St. Luke's University Health Network, Bethleham, PA, 3St. Luke's University Health Network, Bethlehem, PA, 4St. Luke's Medical Center, Bethlehem, PA, 5Christiana Care Health System, Newark, DE, United States
 
7:00 AM
395
Preoperative risk factors to predict lymph node metastasis in early stage endometrial cancer
J. G. Ross, J. J. Hamner, W. Alston, T. W. Wong, J. Daggy and E. C. Rossi
Indiana University School of Medicine, Indianapolis, IN
 
7:00 AM
396
Platinum-free interval is a predictor of survival for recurrent, advanced stage uterine papillary serous carcinoma
L. L. Holman1, L. E. Dockery2, P. T. Soliman1, N. Pal3, A. H. Klopp3, R. Broaddus3, T. Shiozaki4, N. D. Fleming3, M. F. Munsell1, K. H. Lu1 and S. N. Westin1
1The University of Texas MD Anderson Cancer Center, Houston, TX, 2Tufts New England Medical Center, Boston, MA, 3The University of Texas, MD Anderson Cancer Center, Houston, TX, 4Mie University, Tokyo, Japan
 
7:00 AM
397
Prognostic factors for paraaortic lymph node metastasis in endometrial cancer
G. Baiocchi, C. Faloppa, W. R. Camarco, L. Badiglian-Filho, H. Mantoan, L. Y. Kumagai, E. Fukazawa, L. De Brot and A. A. B. A. Costa
A.C. Camargo Cancer Center, São Paulo, Brazil
 
7:00 AM
398
Oxidative stress biomarkers and risk of endometrial cancer
E. A. Salinas1, S. A. Wernimont1, K. A. Mapuskar1, L. I. Szweda2, M. L. McCormick1, J. Gonzalez-Bosquet1, D. Spitz1 and M. J. Goodheart1
1University of Iowa Hospitals and Clinics, Iowa City, IA, 2Oklahoma Medical Research Foundation, Oklahoma City, OK
 
7:00 AM
399
Sensitivity of the intraoperative assessment of myometrial invasion in patients undergoing hysterectomy for endometrial cancer
K. K. Ward1, N. R. Shah2, P. P. Koonings3 and T. A. Harrison3
1University of Florida College of Medicine-Jacksonville, Jacksonville, FL, 2UCSD Rebecca and John Moores Cancer Center, La Jolla, CA, 3Kaiser Permanente Medical Center, San Diego, CA
 
7:00 AM
400
New sentinel lymph node mapping technique by endometrial instillation of vital dye
A. H. Hamed1, M. de Leon2 and G. Del Priore3
1University of Cambridge, Cambridge, United Kingdom, 2Indiana University School of Medicine, Indianapolis, IN, 3Morehouse School of Medicine, Atlanta, GA
 
7:00 AM
401
Mutations in the PIK3 pathway as a major determinant of trastuzumab resistance in uterine serous carcinoma
J. D. Black1, S. Lopez2, S. Bellone1, C. L. Schwab1, D. P. English1, D. M. Roque3, D. A. Silasi1, E. S. Ratner1, M. Azodi1, T. J. Rutherford1, P. E. Schwartz1 and A. Santin1
1Yale University School of Medicine, New Haven, CT, 2University Campus Bio-Medico of Rome, Rome, Italy, 3University of Maryland School of Medicine, Baltimore, MD
 
7:00 AM
402
Green (IGC) fluorescence directed sentinel lymph node (SLN) biopsy in women with endometrial and cervical cancer
A. Urh1, K. M. Robison1, C. Raker1, M. Steinhoff1, P. A. DiSilvestro1, C. K. McCourt2, C. Mathews1, A. R. Stuckey1, C. O. Granai1 and R. G. Moore1
1Women and Infants Hospital, Brown University, Providence, RI, 2Washington University School of Medicine, St Louis, MO
 
7:00 AM
403
Survivors of uterine malignancy have greater healthcare needs than the general population
K. C. Kurnit1, K. K. Ward2, L. M. Bean1, M. T. McHale1, C. C. Saenz1 and S. C. Plaxe1
1UCSD Rebecca and John Moores Cancer Center, La Jolla, CA, 2University of Florida College of Medicine-Jacksonville, Jacksonville, FL
 
7:00 AM
405
Does plastic surgical consultation improve the outcome of patients undergoing radical vulvectomy for squamous cell carcinoma of the vulva?
E. M. Aviki, K. M. Esselen, S. M. Barcia, N. S. Horowitz, C. M. Feltmate, R. S. Berkowitz, M. R. Nucci and M. G. Muto
Brigham and Women's Hospital/Harvard University, Boston, MA
 
7:00 AM
404
Adjuvant vaginal brachytherapy decreases the risk of vaginal recurrence in patients with stage I non-invasive uterine papillary serous carcinoma
H. Mahdi1, P. G. Rose1, M. Elshaikh2, A. R. Munkarah2, D. Isrow2, S. Singh3, S. E. Waggoner3, R. Ali-Fehmi4, J. Harding5, R. T. Morris6 and R. DeBernardo1
1Cleveland Clinic, Cleveland, OH, 2Henry Ford Health System, Detroit, MI, 3University Hospitals Case Medical Center, Cleveland, OH, 4Wayne State University, Detroit, MI, 5Case Western Reserve Univesity, Cleveland, OH, 6Wayne State University School of Medicine, Detroit, MI
 
7:00 AM
406
Comparing the natural history and survival of vulvar sarcoma and squamous cell carcinoma: an analysis 11,677 cases in the Surveillance, Epidemiology, and End Results database
T. Ghezelayagh1,2, J. A. Rauh-Hain3 and W. B. Growdon3
1Harvard School of Public Health, Boston, MA, 2UCSF School of Medicine, San Francisco, CA, 3Massachusetts General Hospital/Harvard University, Boston, MA
 
7:00 AM
407
The role of endometrial biopsy in the preoperative detection of uterine leiomyosarcoma
E. M. Hinchcliff1, K. M. Esselen1, J. Watkins2, J. A. Rauh-Hain3, T. Oduyebo1, M. del Carmen4, B. Quade2 and M. G. Muto1
1Brigham and Women's Hospital/Harvard University, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3Massachusetts General Hospital/Harvard University, Boston, MA, 4Massachusetts General Hospital, Boston, MA
 
7:00 AM
408
Trends in the treatment of uterine leiomyosarcoma in the Medicare population
O. W. Foley1, J. A. Rauh-Hain1, J. T. Clemmer1, R. M. Clark1, T. R. Hall1, E. Diver2, J. O. Schorge1 and M. del Carmen1
1Massachusetts General Hospital/Harvard University, Boston, MA, 2Brigham and Women's Hospital/Massachusetts General Hospital, Boston, MA
 
7:00 AM
409
Gynecologic oncologist as surgical consultant: intraoperative consultations during general gynecologic surgery as an important focus of gynecologic oncology training
E. M. Aviki, J. A. Rauh-Hain, R. M. Clark, T. R. Hall, L. R. Berkowitz, D. M. Boruta II, W. B. Growdon, J. O. Schorge and A. Goodman
Massachusetts General Hospital/Harvard University, Boston, MA
 
7:00 AM
410
Small cell neuroendocrine carcinoma of the cervix: does treatment sequence and type of hysterectomy improve outcomes?
B. C. Orr1, J. F. Lin2,3, S. Beriwal2, R. P. Edwards2, J. L. Kelley III2, A. B. Olawaiye2, J. T. Comerci2, M. Huang2, M. Courtney-Brooks4 and P. Sukumvanich2
1UPMC- Magee Womens Hospital, Pittsburgh, PA, 2Magee-Womens Hospital of UPMC, Pittsburgh, PA, 3Bay Area Gynecology Oncology, Los Gatos, CA, 4University of Pittsburgh Medical Center, Pittsburgh, PA
 
7:00 AM
411
The role of lymphadenectomy and radiation therapy for malignant mixed Müllerian uterine cancers
A. B. Gardner1, D. S. Kapp2 and J. K. Chan3
1Palo Alto Medical Foundation Research Institute, Palo Alto, CA, 2Stanford University, Stanford, CA, 3California Pacific & Palo Alto Medical Foundation / Sutter Research Institute, San Francisco, CA
 
7:00 AM
412
Evaluation of the number of copies of the TOP2A gene and its protein expression in uterine leiomyosarcoma
G. Baiocchi, I. W. Cunha, F. Poliseli, H. Mantoan, C. Faloppa, L. Y. Kumagai, L. De Brot and J. Vassallo
A.C. Camargo Cancer Center, São Paulo, Brazil
 
7:00 AM
413
Comparison of EP regimen for treatment of gestational trophoblastic neoplasia with 5-FU+KSM regimen and the analysis of resistance related factors
J. Li Sr.
Qilu Hospital,Shandong University, Jinan, China
 
7:00 AM
414
Utility of risk weighted surgical pathological risk factors in predicting survival outcomes among women with vulvar cancer: a population based study
C. A. Bradley1, N. Opper2, M. Cockburn2, L. D. Roman1 and K. Matsuo1
1LAC+USC Medical Center, Los Angeles, CA, 2University of Southern California, Los Angeles, CA
 
7:00 AM
415
A retrospective assessment of the role of radiation in treatment of uterine carcinosarcoma
B. B. Mize, Y. C. Lee, J. Tolentino, A. Strasburger, G. M. Salame, A. Moron and O. Abulafia
SUNY Downstate, Brooklyn, NY
 
7:00 AM
416
Identification of somatic mutations in uterine leiomyosarcomas
M. R. Barrett1, A. Quinlan1, P. Kumar1, C. Johnson1, J. Bryant1, C. Moskaluk1, A. Dutta1 and A. Jazaeri2
1University of Virginia, Charlottesville, VA, 2The University of Texas MD Anderson Cancer Center, Houston, TX
 
7:00 AM
417
Perivascular epithelioid cell tumor (PEComa) of the gynecologic tract: a single institution clinicopathologic review
J. A. Ducie1, R. Murali1, D. Hyman1, M. L. Hensley2, R. A. Soslow1 and O. Zivanovic1
1Memorial Sloan Kettering Cancer Center, New York, NY, 2Weill Cornell Medical College, New York, NY
 
7:00 AM
418
The GRO-SNaPET study: preliminary data on the prediction of lymphonodal status by sentinel lymph node biopsy combined with 18FDG-PET/CT to overcome the current limits of vulvar cancer treatment
G. Garganese, S. M. Fragomeni, V. Rufini, G. Perotti, L. Zagaria, A. Collarino, M. T. Evangelista, A. Naldini, C. Rossitto, A. Giordano and G. Scambia
Catholic University of the Sacred Heart, Rome, Italy
 
7:00 AM
419
Laparoscopy compared to laparotomy in the management of granulosa cell tumors of the ovary
J. Nakayama1, E. Saks2, E. Pelkofski3, J. Edwards4, J. E. Stine5, A. A. Secord4, P. A. Gehrig5 and L. Duska2
1University Hospital of Cleveland, Cleveland, OH, 2University of Virginia School of Medicine, Charlottesville, VA, 3University of Virginia Medical Center, Charlottesville, VA, 4Duke University Medical Center, Durham, NC, 5University of North Carolina at Chapel Hill, Chapel Hill, NC
 
7:00 AM
420
Epidemiology of gestational trophoblastic disease in Hawaii: a retrospective review
C. V. Marzo1, K. Thompson1,2,3 and P. Tauchi-Nishi1,4
1University of Hawaii John A. Burns School of Medicine, Honolulu, HI, 2Kapiolani Medical Center for Women and Children, Honolulu, HI, 3Clinical Laboratories of Hawaii, Honolulu, HI, 4Queen's Medical Center, Honolulu, HI
 
7:00 AM
421
Identifying therapeutic options in small cell cervical cancer by multiplatform evaluation of biomarker alterations
M. Frumovitz1, J. K. Burzawa1, R. L. Coleman1, S. K. Reddy2, I. Astsaturov3, S. Z. Millis2 and J. Brown4
1The University of Texas MD Anderson Cancer Center, Houston, TX, 2Caris Life Sciences, Irving, TX, 3Fox Chase Cancer Center, Philadelphia, PA, 4The University of Texas, MD Anderson Cancer Center, Houston, TX
 
7:00 AM
422
The impact of depression on survival in uterine carcinosarcoma
S. H. Bush1, R. M. Whynott2, R. Abdallah3, Y. Xiong3, H. S. Chon3, S. M. Apte3, R. M. Wenham3, P. Judson1, J. M. Lancaster3 and M. M. K. Shahzad3
1H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, 2University of South Florida, Tampa, FL, 3H. Lee Moffitt Cancer Center, Tampa, FL
 
7:00 AM
423
The role of adjuvant therapy in early stage high grade uterine leiomyosarcoma
M. Klobocista1, M. A. Schwartz1, A. Van Arsdale2, A. A. Yessaian3, R. Sposto4, L. I. Muderspach5 and L. Roman4
1Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, 2Montefiore Medical Center, Scarsdale, NY, 3University of Southern California, Encino, CA, 4Keck School of Medicine of USC, Los Angeles, CA, 5University of Southern California, Los Angeles, CA
 
7:00 AM
424
Comparing survival of vulvar melanoma and squamous cell carcinoma: an analysis of 13,112 patients in the Surveillance, Epidemiology and End Results database
T. Ghezelayagh1,2, J. A. Rauh-Hain3 and W. B. Growdon3
1Harvard School of Public Health, Boston, MA, 2UCSF School of Medicine, San Francisco, CA, 3Massachusetts General Hospital/Harvard University, Boston, MA
 
7:00 AM
425
Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174?
C. R. Miller1, N. P. Chappell1, C. A. Leath III2, N. T. Phippen3, L. J. Havrilesky4 and J. C. Barnett1
1Brooke Army Medical Center, Fort Sam Houston, TX, 2University of Alabama at Birmingham, Birmingham, AL, 3Gynecologic Oncology Service, Department of Obstetrics and Gynecology, Murtha Cancer Center, Walter Reed National Military Medical Center, Bethesda, MD, 4Duke University Medical Center, Durham, NC
 
7:00 AM
426
Genetic counseling and evaluation of BRCA mutations in an African American female population in the Deep South
C. L. Walters Haygood, M. B. Farmer, R. D. Alvarez, C. A. Leath III and J. M. Estes
University of Alabama at Birmingham, Birmingham, AL
 
7:00 AM
427
Cost comparison among different genetic testing strategies in women with epithelial ovarian cancer
M. Lopez-Acevedo1, A. H. Buchanan2, A. A. Secord1, P. S. Lee2, C. Fountain2, E. R. Myers2, D. E. Cohn3, S. D. Reed2 and L. J. Havrilesky1
1Duke University Medical Center, Durham, NC, 2Duke University Hospital, Durham, NC, 3The Ohio State University, Columbus, OH
 
7:00 AM
428
New cases of small cell carcinoma of the ovary, hypercalemic type caused by germline SMARCA4 mutations: an under-diagnosed entity?
L. Witkowski1, N. Donini2, J. A. Knost2, A. Berchuck3, D. L. Thull4, C. Lazaro5, M. Longy6, W. G. McCluggage7, B. A. Clarke8, M. Hasselblatt9 and W. D. Foulkes1
1McGill University, Montreal, QC, Canada, 2Illinois CancerCare, Peoria, IL, 3Duke University Medical Center, Durham, NC, 4University of Pittsburg Medical Center, Pittsburgh, PA, 5Catalan Institute of Oncology, Barcelona, Spain, 6Institut Bergonie, Bordeaux, France, 7Royal Group of Hospitals Trust, Belfast, Northern Ireland, 8University of Toronto, Toronto, ON, Canada, 9University Hospital Münster, Münster, Germany
 
7:00 AM
429
Quality of BRCA counseling by gynecologic oncologists: a patient survey based analysis
J. C. Makin, E. K. Anderson, M. J. Cunningham and R. Agarwal
SUNY Upstate Medical University, Syracuse, NY
 
7:00 AM
430
Early detection of ovarian cancer via a self-sampling screening test of vaginal secretions: feasibility and patient acceptance
R. P. Rocconi1, J. M. Scalici1, D. Billheimer2, B. Mannakee2, L. Schambeau1, L. Pannell1 and M. A. Finan1
1University of South Alabama-Mitchell Cancer Institute, Mobile, AL, 2The University of Arizona Health Network, Tucson, AZ
 
7:00 AM
431
Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with cisplatin resistance in ovarian cancer
M. C. De Leon, H. Cardenas, R. Emerson and D. Matei
Indiana University School of Medicine, Indianapolis, IN
 
7:00 AM
432
Hyperthermic intraperitoneal chemotherapy for treatment of ovarian and primary peritoneal cancer: single institutional experience
V. Andikyan1, P. Tabrizian2, S. Farag2, J. Fields1, V. Kolev3, J. Rahaman2, D. A. Fishman2, U. Sarpel2, K. Zakashansky1 and D. Labow2
1Icahn School of Medicine at Mount Sinai, New York, NY, 2Mount Sinai School of Medicine, New York, NY, 3Beth Israel Medical Center, New York, NY
 
7:00 AM
433
Determination of HE4-mediated roles in tumor immune system modulation in epithelial ovarian cancer (EOC)
A. Urh, N. Romano, A. Han, J. Ribeiro, N. Yano, K. Kim, R. Singh and R. G. Moore
Women and Infants Hospital, Brown University, Providence, RI
 
7:00 AM
434
Multi-institutional validation of decreased survival with venous thromboembolism in ovarian clear cell carcinoma
M. Holzapfel1, J. J. Mueller2, M. M. Leitao2, C. C. Gunderson3, K. N. Moore3, B. K. Erickson4, C. A. Leath III4, E. S. Diaz5 and C. Walsh1
1Cedars-Sinai Medical Center, Los Angeles, CA, 2Memorial Sloan Kettering Cancer Center, New York, NY, 3The University of Oklahoma, Oklahoma City, OK, 4University of Alabama at Birmingham, Birmingham, AL, 5Northshore University Health System, Evanston, IL
 
7:00 AM
435
Recurrent ovarian cancer patients with 3-6 month treatment-free interval or 1-2 prior chemotherapy regimens might get benefit from tumor chemosensitivity assay directed chemotherapy
N. Li1, Y. T. Gao2, R. Zhang2, X. G. Li2, Y. C. Sun2, N. Li2, B. Li2, W. Zhang3 and L. Y. Wu4
1Cancer Hostpital, Chinese Academy of Medical Sciences, Beijing, China, 2Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China, 3Cancer Hospital (Institute), Chinese Academy of Medical Sciences, Beijing, China, 4Cancer Hospital, Chinese Academy of Medical Sciences,, Beijing, China
 
7:00 AM
436
Risk stratification and outcomes of women undergoing surgery for ovarian cancer
S. S. Patankar1, W. M. Burke2, J. Y. Hou1, A. I. Tergas2, C. Ananth1, Y. Huang1 and J. D. Wright2
1Columbia University College of Physicians and Surgeons, New York, NY, 2NYP/Columbia University Medical Center, New York, NY
 
7:00 AM
437
AKT survival signaling as a determinant of ovarian cancer chemoresistance and clinical outcome
E. Al Sawah1, Y. Xiong2, B. Boac3, F. Abbasi2, D. Marchion2, I. Ramirez1, S. H. Bush1, C. McClung3, P. L. Judson Lancaster2 and J. M. Lancaster2
1University of South Florida College of Medicine, Tampa, FL, 2H. Lee Moffitt Cancer Center, Tampa, FL, 3H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
 
7:00 AM
438
Patterns of care and survival in a matched case-control study of intraperitoneal chemotherapy in a national population-based cohort of elderly ovarian cancer patients
L. A. Meyer1, W. He1, H. Zhao1, C. C. L. Sun1, A. Wright2, D. C. Bodurka1, K. H. Lu1 and S. H. Giordano1
1The University of Texas MD Anderson Cancer Center, Houston, TX, 2Brigham and Women's Hospital/Dana Farber Cancer Institute, Boston, MA
 
7:00 AM
439
Should neoadjuvant chemotherapy be preferred to an alternative treatment for advanced ovarian cancer: comparison of neoadjuvant chemotherapy followed by interval debulking surgery and primary debulking surgery in patients with advanced ovarian cancer
J. Liu
Cancer Center, Sun Yat-Sen University, Guangzhou, China
 
7:00 AM
440
Survival and toxicity of a modified GOG 172 IP chemotherapy regimen in patients with ovarian, fallopian tube or primary peritoneal carcinoma
D. Becker, C. L. Walters Haygood, B. Smith and K. S. Bevis
University of Alabama at Birmingham, Birmingham, AL
 
7:00 AM
441
Vitamin D suppresses ovarian cancer invasion by inhibiting cytokine expression and NFκB signaling
P. Lungchukiet1, Y. Sun1, Q. Waise1, Y. Xiong2, D. Marchion2, J. M. Lancaster2, S. Nicosia1, X. Xhang1 and W. Bai1
1University of South Florida College of Medicine, Tampa, FL, 2H. Lee Moffitt Cancer Center, Tampa, FL
 
7:00 AM
442
Bioenergetic adaptations in chemo-resistant ovarian cancer cells
R. Rattan1, S. Dar1, J. Chhina1, M. Deshpande2, T. E. Buekers1, S. Giri1 and A. R. Munkarah1
1Henry Ford Health System, Detroit, MI, 2Henry Ford Hospital, Detroit, MI
 
7:00 AM
443
Serum interleukin-6 is a biomarker of survival in women with advanced stage and optimally resected epithelial ovarian cancer
S. A. Martin, B. Y. Karlan, C. Walsh, I. Cass, B. J. Rimel and A. J. Li
Cedars-Sinai Medical Center, Los Angeles, CA
 
7:00 AM
444
A state by state analysis of BRCA1 and BRCA2 testing in patients with ovarian cancer
T. J. Herzog1, J. Saam2, C. Arnell2 and R. J. Wenstrup2
1University of Cincinnati, Cincinnati, OH, 2Myriad Genetic Laboratories, Inc., Salt Lake City, UT
 
7:00 AM
445
Association of AMPK signaling pathway with tumor response to treatment in ovarian cancer
H. M. Madi1, Z. Al-Wahab2, L. Poisson3, C. Burmeister1, S. Hensley Alford3, R. T. Morris2, R. Rattan3 and A. R. Munkarah3
1Henry Ford Hospital, Detroit, MI, 2Wayne State University, Detroit, MI, 3Henry Ford Health System, Detroit, MI
 
7:00 AM
446
Predictive value of the age-adjusted Charlson comorbidity index on perioperative complications and survival in patients undergoing surgery for advanced ovarian cancer
R. S. Suidan, M. M. Leitao, O. Zivanovic, G. J. Gardner, Y. Sonoda, D. A. Levine, E. Jewell, C. L. Brown, N. R. Abu-Rustum and D. S. Chi
Memorial Sloan Kettering Cancer Center, New York, NY
 
7:00 AM
447
Prognostic factors in recurrent epithelial ovarian cancer
G. Baiocchi, A. A. B. A. Costa, C. V. V. Amorim, A. Saito, H. Mantoan, C. Faloppa, L. Y. Kumagai, L. Badiglian-Filho, A. P. G. Guimaraes and S. M. Sanches
A.C. Camargo Cancer Center, São Paulo, Brazil
 
7:00 AM
448
Complications from surgeries prompted by ovarian cancer screening
R. W. Miller1, E. J. Pavlik2, L. A. Baldwin1, J. Lefringhouse2, E. Ueland1, H. Brown1, K. M. Ladd1, B. Huang2, C. P. Desimone1, J. R. Vannagell1 and F. R. Ueland1
1University of Kentucky Medical Center, Lexington, KY, 2University of Kentucky, Lexington, KY
 
7:00 AM
449
The initial costs of caring for patients with advanced ovarian cancer
R. R. Urban1, H. He1, R. Alfonso1, M. M. Hardesty2 and B. A. Goff1
1University of Washington Medical Center, Seattle, WA, 2Alaska Women's Cancer Care, Anchorage, AK
 
7:00 AM
450
Paraneoplastic neurologic syndrome in ovarian carcinoma
H. A. Oughli1, N. Balakrishnan1, M. F. Munsell1, T. Shiozaki2, M. Frumovitz1, P. T. Soliman1, K. M. Schmeler1, P. T. Ramirez1, A. M. Nick1, B. J. O' Brien1 and S. N. Westin1
1The University of Texas MD Anderson Cancer Center, Houston, TX, 2Mie University, Tokyo, Japan
 
7:00 AM
451
Comorbid case-mix and predictors of inpatient admissions or death among ovarian cancer patients presenting to emergency departments in the United States
A. Walter1, K. N. Slaughter2, C. C. Gunderson2, K. N. Moore2 and G. Skrepnek1
1The University of Oklahoma, Stephenson Cancer Center, Oklahoma City, OK, 2The University of Oklahoma, Oklahoma City, OK
 
7:00 AM
452
Insight into the relationship between disease burden at diagnosis and surgical resection on chemotherapy resistance and shorter progression free survival in epithelial ovarian, fallopian tube and primary peritoneal carcinoma in GOG 182
C. A. Hamilton1, A. Miller2, B. J. Rungruang3, S. D. Richard4, N. Rodriguez5, N. S. Horowitz6, G. L. Maxwell7 and T. C. Krivak8
1Walter Reed National Military Medical Center, Bethesda, MD, 2Gynecologic Oncology Group, Buffalo, NY, 3Georgia Reagents University, Evans, GA, 4Hahnemann University Hospital/Drexel University College of Medicine, Philadelphia, PA, 5Southern California Permanente Medical Group, Irvine, CA, 6Harvard Medical School, Boston, MA, 7Inova Fairfax Hospital, Falls Church, VA, 8Western Pennsylvania Hospital, Pittsburgh, PA
 
7:00 AM
453
The effects of combined MEK inhibition and antiestrogen therapy in the treatment of ovarian cancer
K. E. Hew1, P. Miller1, D. El-Ashry1, Z. Wei2, J. Sun1, G. Zhang3, W. Guo4, P. Brafford3, G. Mills4, J. Slingerland1 and F. Simpkins5
1University of Miami Miller School of Medicine, Miami, FL, 2New Jersey Institute of Technology, Newark, NJ, 3Wistar Institute, Philadelphia, PA, 4The University of Texas MD Anderson Cancer Center, Houston, TX, 5University of Pennsylvania, Philadelphia, PA
 
7:00 AM
454
Association of high-density lipoprotein cholesterol with ovarian cancer diagnosis
S. Hensley Alford1, R. Rattan1, M. Diaz2 and A. R. Munkarah1
1Henry Ford Health System, Detroit, MI, 2Henry Ford Hospital, Detroit, MI
 
7:00 AM
455
Lymphocyte nadir and reconstitution during chemotherapy predicts survival in ovarian cancer patients
R. Brightwell, K. O. Odunsi and S. B. Lele
Roswell Park Cancer Institute, Buffalo, NY
 
7:00 AM
456
The genomic landscapes of high grade serous ovarian cancers: contrasting long term survivors and ‘platinum-resistant' disease
J. N. McAlpine1,2, Y. Wang1, B. Gilks2, D. Huntsman2 and S. P. Shah1,2
1BC Cancer Agency, Vancouver, BC, Canada, 2University of British Columbia, Vancouver, BC, Canada
 
7:00 AM
457
Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancers: is there a role?
M. M. Boisen1, S. D. Richard2, R. P. Edwards1, J. L. Kelley III1 and M. Huang1
1Magee-Womens Hospital of UPMC, Pittsburgh, PA, 2Hahnemann University Hospital/Drexel University College of Medicine, Philadelphia, PA
 
7:00 AM
458
Impact of perioperative fluid status on surgical outcomes in patients with epithelial ovarian cancer
M. G. Desale1, A. K. Sinno2, A. Angarita3, E. J. Tanner III2, A. Nickles Fader2, R. L. Stone2, K. Levinson2 and K. C. Long3
1Johns Hopkins School of Medicine, Baltimore, MD, 2Johns Hopkins Hospital, Baltimore, MD, 3Johns Hopkins Medical Institutions, Baltimore, MD
 
7:00 AM
459
Patterns of cancer recurrence in African American patients with high grade epithelial ovarian carcinoma
S. Singh, A. Armstrong, G. Pettigrew and K. E. Resnick
University Hospitals Case Medical Center, Cleveland, OH
 
7:00 AM
460
Serous cancer precursors outside of BRCA: could you miss a STIC and does it matter?
E. Saks1, L. H. Clark2, K. H. Kim2, L. Duska1 and L. A. Cantrell1
1University of Virginia School of Medicine, Charlottesville, VA, 2University of North Carolina at Chapel Hill, Chapel Hill, NC
 
7:00 AM
461
Radical cytoreductive surgery for ovarian cancer in the United States: trends and associated factors over the past twenty years
A. K. Sinno, A. Nickles Fader, E. J. Tanner III, R. L. Stone, K. Levinson and K. C. Long
Johns Hopkins Hospital, Baltimore, MD
 
7:00 AM
462
Applicability of ACOG/SGO referral criteria to an urban inner city population for adnexal masses
A. Battarbee1, A. E. Strohl1, L. Zimmerman2, A. Patel1 and R. Malapati2
1Northwestern University Feinberg School of Medicine, Chicago, IL, 2John H. Stroger Hospital, Chicago, IL
 
7:00 AM
463
Refusal of recommend chemotherapy for ovarian cancer: risk factors and outcomes, a National Cancer Database study
J. F. Lin1,2, B. A. Cliby3, G. S. Leiserowitz4, A. I. Tergas5, R. E. Bristow6 and S. Wallace7
1Magee-Womens Hospital of UPMC, Pittsburgh, PA, 2Bay Area Gynecology Oncology, Los Gatos, CA, 3Mayo Clinic, Rochester, MN, 4UC Davis Comprehensive Cancer Center, Sacramento, CA, 5NYP/Columbia University Medical Center, New York, NY, 6University of California, Irvine, Irvine, CA, 7Mayo Clinic College of Medicine, Rochester, MN
 
7:00 AM
464
Survival of the fittest: can exercise prolong the time to ovarian cancer recurrence?
M. Onstad, K. L. Ring, J. B. Pakish, Q. Zhang, J. Celestino, K. H. Lu and R. E. Schmandt
The University of Texas MD Anderson Cancer Center, Houston, TX
 
7:00 AM
465
Factors affecting ovarian cancer treatment in the octogenarian patient population
N. Rasool, T. E. Buekers, R. K. Hanna, A. R. Munkarah and S. Hensley Alford
Henry Ford Health System, Detroit, MI
 
7:00 AM
466
Cost effectiveness of primary debulking surgery when compared to neoadjuvant chemotherapy in the management of stage IIIC and IV epithelial ovarian cancer
G. K. Forde1, J. Chang2, A. Ziogas2 and R. E. Bristow2
1University of California at Irvine Medical Center, Orange, CA, 2University of California, Irvine, Irvine, CA
 
7:00 AM
467
Poor prognosis after conservative surgery in stage I mucinous epithelial ovarian cancer
P. S. Jung, S. W. Lee, J. Y. Park, D. S. Suh, D. Y. Kim, J. H. Kim, Y. M. Kim, Y. T. Kim and J. H. Nam
University of Ulsan College of Medicine, ASAN Medical Center, Seoul, South Korea
 
7:00 AM
468
FIGO staging criteria is a meaningful clinical threshold for evaluating molecular signatures in serous ovarian cancer patients
N. T. Phippen1, G. Wang2, N. W. Bateman2, W. J. Lowery3, M. P. Stany3, C. A. Hamilton3, G. L. Maxwell4, T. P. Conrads2 and K. M. Darcy2
1Gynecologic Oncology Service, Department of Obstetrics and Gynecology, Murtha Cancer Center, Walter Reed National Military Medical Center, Bethesda, MD, 2Gynecologic Cancer Center of Excellence, Annandale, VA, 3Walter Reed National Military Medical Center, Bethesda, MD, 4Inova Fairfax Hospital, Falls Church, VA
 
7:00 AM
469
Improving NCCN guideline-adherent care for ovarian cancer: value of an intervention
J. A. Dottino1, B. A. Cliby2, E. R. Myers3, R. E. Bristow4 and L. J. Havrilesky1
1Duke University Medical Center, Durham, NC, 2Mayo Clinic, Rochester, MN, 3Duke University Hospital, Durham, NC, 4University of California, Irvine, Irvine, CA
 
7:00 AM
470
Gestational diabetes may increase risk of endometrial cancer later in life: results of a population based study in Washington State, 1987-2012
T. L. Beck1, R. R. Urban1, S. D. Reed1, B. A. Mueller2, S. E. Hawes2 and P. D. Wartko2
1University of Washington Medical Center, Seattle, WA, 2University of Washington School of Public Health, Seattle, WA
 
7:00 AM
471
Distance to specialist care is associated with survival in patients with gynecologic malignancies
A. J. Hicks1, Y. Xiong2, D. Marchion2, G. Abboud1, G. Oakley1, J. M. Lancaster2, D. F. Silver3 and N. Bou Zgheib1
1Marshall University School of Medicine, Huntington, WV, 2H. Lee Moffitt Cancer Center, Tampa, FL, 3The Women's Institute for Gynecologic Cancer & Special Pelvic Surgery, Coopersburg, PA
 
7:00 AM
472
Racial disparities and the effect of time on ovarian cancer survival among cases identified through the National Cancer Database
C. E. Joslin1,2,3, K. C. Brewer2, A. Beckmeyer-Borowko2, C. E. Peterson4, M. A. Otoo1,5, K. Hoskins1,3 and F. Davis6
1University of Illinois College of Medicine, Chicago, IL, 2University of Illinois at Chicago School of Public Health, Chicago, IL, 3University of Illinois at Chicago Cancer Center, Chicago, IL, 4University of Illinois Chicago, Chicago, IL, 5University of Illinis at Chicago School of Public Health, Chicago, IL, 6University of Alberta School of Public Health, Edmonton, AB, Canada
 
7:00 AM
473
Does access to health insurance and care positively impact disparities in cervical dysplasia and invasive cancer?
T. Shemshedini1, T. L. Pua2, F. Moy3, S. S. Tedjarati4 and T. S. Pradhan1
1New York Medical College/Westchester Medical Center, Valhalla, NY, 2New York Medical College, Hawthorne, NY, 3New York Medical College, Valhalla, NY, 4Westchester Medical Center, Valhalla, NY
 
7:00 AM
474
HPV vaccination rates among US medical students
T. R. Buchanan Jr.1, M. L. Podolsky1, D. Farabaugh1 and S. D. Richard2
1Drexel University College of Medicine, Philadelphia, PA, 2Hahnemann University Hospital/Drexel University College of Medicine, Philadelphia, PA
 
7:00 AM
475
Complementary and alternative medicine use in patients with gynecologic cancers
R. Abdallah, Y. Xiong, J. M. Lancaster and P. L. Judson Lancaster
H. Lee Moffitt Cancer Center, Tampa, FL
 
7:00 AM
476
Real world effectiveness of minimally invasive hysterectomy for uterine cancer
C. R. Duffy, W. M. Burke, J. Y. Hou, A. I. Tergas and J. D. Wright
Columbia University College of Physicians and Surgeons, New York, NY
 
7:00 AM
477
Distribution of endometrial cancer histology in a southern urban safety net hospital
R. K. Lee and R. P. Matthews
Morehouse School of Medicine, Atlanta, GA
 
7:00 AM
478
National age standardized rate (ASR) of uterine corpus cancer (CC) correlates with Human Development Index (HDI), analysis of data from 154 countries
P. M. Workman, S. C. Plaxe, L. M. Bean, C. C. Saenz and M. T. McHale
UCSD Rebecca and John Moores Cancer Center, La Jolla, CA
 
7:00 AM
479
Multimodal pain control is associated with reduced hospital stay following open abdominal hysterectomy
M. Ulm1, J. Wan1, P. Jennings2 and J. T. Santoso3
1University of Tennessee Health Science Center, Memphis, TN, 2University of Tennessee, Memphis, TN, 3University of Tennessee West Clinic, Memphis, TN
 
7:00 AM
480
Depression scores before and after in-office evaluations in patients undergoing ovarian cancer screening
S. Farag1, M. Chu2, L. D. Nguyen1, V. Andikyan3, E. B. Pereira1, E. L. Moshier1, S. Wilson1, S. Vaidya1 and D. A. Fishman1
1Mount Sinai School of Medicine, New York, NY, 2SUNY-Downstate, Brooklyn, NY, 3Icahn School of Medicine at Mount Sinai, New York, NY
 
7:00 AM
481
The impact of endocrine therapy on sexual dysfunction in women with early stage breast cancer
M. Lee1, H. H. Chung2, J. W. Kim2, N. H. Park2 and Y. S. Song2
1Seoul National University College of Medicine, Seoul, South Korea, 2Seoul National University, Seoul, South Korea
 
7:00 AM
482
The associations between physical activity behaviors, body composition and quality-of-life among ethnically diverse endometrial cancer survivors
A. Rossi1,2,3, C. E. Garber3, G. Kaur4, G. L. Goldberg4, Y. S. Kuo4, X. Xue5 and N. S. Nevadunsky4
1Montefiore Medical Center, New York, NY, 2Long Island University - Brooklyn, Brooklyn, NY, 3Teachers College Columbia University, New York, NY, 4Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, 5Albert Einstein Cancer Center, Bronx, NY
 
7:00 AM
483
The effect of gynecologic cancer on patient's depression and anxiety: prospective study
T. T. Ilhan1, A. K. Kebapcilar2, T. I. Ilhan3, T. C. Cakir2, S. A. Yilmaz4, C. Celik5 and B. B. B. Bakbak2
1Selcuk University Medicine Faculty, Konya, Turkey, 2university of selcuk, Konya, Turkey, 3Beyhekim state hospital, Konya, Turkey, 4Selçuk University Medicine Faculty, Konya, Turkey, 5Selçuk University, Konya, Turkey
 
7:00 AM
484
Patient attitudes regarding the use of power morcellation during laparoscopic hysterectomy
M. T. Dhanani, A. E. Wells, T. L. Montgomery and T. A. Dinh
Mayo Clinic Florida, Jacksonville, FL
 
7:00 AM
485
How equal is end of life care among gynecologic oncology patients?
J. S. Taylor, A. J. Brown, L. S. Prescott, C. C. L. Sun, L. M. Ramondetta and D. C. Bodurka
The University of Texas MD Anderson Cancer Center, Houston, TX
 
7:00 AM
486
Identifying gynecologic oncology patients with high symptom burden
M. Rowland1, R. Ruskin1, K. N. Moore2, J. L. Walker2, L. M. Landrum2 and M. Matzo3
1The University of Oklahoma, Stephenson Cancer Center, Oklahoma City, OK, 2The University of Oklahoma, Oklahoma City, OK, 3University of Oklahoma Health Sciences Center, Oklahoma City, OK
 
7:00 AM
487
Improvement in symptom burden within one day after palliative care consultation in a cohort of gynecologic oncology inpatients
C. Lefkowits1, W. Teuteberg1, M. Courtney-Brooks1, P. Sukumvanich2, R. Ruskin3 and J. L. Kelley III2
1University of Pittsburgh Medical Center, Pittsburgh, PA, 2Magee-Womens Hospital of UPMC, Pittsburgh, PA, 3The University of Oklahoma, Stephenson Cancer Center, Oklahoma City, OK
 
7:00 AM
488
Hospice utilization among gynecologic oncology (GO) patients is associated with payer and primary tumor site
M. A. Davis1, K. K. Ward2, N. R. Shah1, L. M. Bean1, C. C. Saenz1, M. T. McHale1 and S. C. Plaxe1
1UCSD Rebecca and John Moores Cancer Center, La Jolla, CA, 2University of Florida College of Medicine-Jacksonville, Jacksonville, FL
 
7:00 AM
489
Patterns of recurrence after pelvic exenteration for cervical and vaginal cancer
G. Baiocchi, C. Faloppa, R. A. R. Oliveira, L. Y. Kumagai, H. Mantoan, L. Badiglian-Filho, A. A. B. A. Costa and G. C. Guimaraes
A.C. Camargo Cancer Center, São Paulo, Brazil
 
7:00 AM
490
Symptom burden in women with advanced or recurrent cervical cancer referred to a supportive care center
L. M. Ramondetta1, Y. J. Kim2, M. F. Munsell1, J. Park2, L. A. Meyer1, C. C. L. Sun1, A. J. Brown1, D. C. Bodurka1 and E. Bruera3
1The University of Texas MD Anderson Cancer Center, Houston, TX, 2Seoul National University Hospital, Seoul, South Korea, 3University of Texas M.D. Anderson Cancer Center, Houston, TX
 
7:00 AM
491
Pelvic radiotherapy does not deteriorate the quality of life of women with gynecologic cancers in long term follow-up: a two-year prospective single center study
G. Yavas1, C. Yavas1, N. U. Dogan2, T. T. Ä°Lhan1, P. Karabagli1, S. Dogan2, O. Ata1, E. Yuce3 and C. Celik4
1Selcuk University, Konya, Turkey, 2Akdeniz University, Antalya, Turkey, 3Ufuk University, Ankara, Turkey, 4Selçuk University, Konya, Turkey
 
7:00 AM
492
Disease recurrence and survival among women with endometrial carcinoma undergoing robotic versus laparoscopic surgery
A. H. Freeman1, A. Barrie1, L. Lyon2, C. Garcia1, L. H. Abbott1, R. D. Littell1 and B. Powell1
1Kaiser Permanente San Francisco Medical Center, San Francisco, CA, 2Kaiser Permanente Medical Group Division of Research, San Francisco, CA
 
7:00 AM
493
Comparison of surgical outcomes in laparoscopic and robotic-assisted surgical management of endometrial cancer
A. Barrie1, A. H. Freeman1, L. Lyon2, C. Garcia1, L. H. Abbott1, R. D. Littell1 and B. Powell1
1Kaiser Permanente San Francisco Medical Center, San Francisco, CA, 2Kaiser Permanente Medical Group Division of Research, San Francisco, CA
 
7:00 AM
494
Current practices and opinions regarding sentinel lymph node biopsy for gynecologic malignancies
P. C. Mayor, E. C. Rossi and J. G. Ross
Indiana University School of Medicine, Indianapolis, IN
 
7:00 AM
495
Survival in patients with uterine carcinosarcoma undergoing sentinel lymph node mapping
M. B. Schiavone1, O. Zivanovic1, Q. Zhou1, M. M. Leitao1, K. Alektiar1, V. Makker1, A. Iasonos2 and N. R. Abu-Rustum1
1Memorial Sloan Kettering Cancer Center, New York, NY, 2Memorial Sloan-Kettering Cancer Center, New York, NY
 
7:00 AM
496
False positive identification of sentinel lymph nodes with robotic fluorescence imaging and ICG in endometrial and cervical cancer
J. J. Hamner1, J. A. Thomes Pepin1, W. Yang2, L. D. Kowalski3, J. M. Scalici4, K. M. Schuler5, L. A. Cantrell6, J. F. Boggess7 and E. C. Rossi1
1Indiana University School of Medicine, Indianapolis, IN, 2University of North Carolina Gillings School of Public Health, Chapel Hill, NC, 3Nevada Surgery and Cancer Care, Las Vegas, NV, 4University of South Alabama-Mitchell Cancer Institute, Mobile, AL, 5Good Samaritan Hospital, Cincinnati, OH, 6University of Virginia School of Medicine, Charlottesville, VA, 7University of North Carolina at Chapel Hill, Chapel Hill, NC
 
7:00 AM
497
Laparoscopic versus laparotomic radical hysterectomies: first minimally invasive cases in Argentina
J. M. Saadi, G. Salvo, R. Orti, G. T. Saraniti and M. Perrotta
Hospital Italiano de Buenos Aires, Capital Federal, Argentina
 
7:00 AM
498
Complications of robotic vaginal cuff closure with barbed versus non-barbed suture
J. C. Makin1, M. Toscano1, E. K. Anderson1, W. D. Bunn2 and M. J. Cunningham1
1SUNY Upstate Medical University, Syracuse, NY, 2GYN Oncology of CNY, PC, East Syracuse, NY
 
7:00 AM
499
Effect of body mass index on conversion rate and complications among patients undergoing robotic surgery for endometrial cancer
E. Dorzin1, L. Nguyen1, E. K. Anderson1, W. D. Bunn2 and M. J. Cunningham1
1SUNY Upstate Medical University, Syracuse, NY, 2GYN Oncology of CNY, PC, East Syracuse, NY
 
7:00 AM
501
Evaluation of a novel combination treatment strategy using patient-derived xenografts of uterine carcinosarcoma
J. Brouwer-Visser, S. Mi, M. Cossio, M. A. Schwartz, T. Hebert, Y. Zou, D. Y. S. Kuo and G. S. Huang
Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY
 
7:00 AM
502
Suppression of ovarian cancer growth and metastasis with HO-3867, a STAT3 inhibitor, in human tissue culture and in an orthotopic mouse model
S. Naidu1, U. Saini1, A. C. ElNaggar2, K. Rath2, B. K. Hemant1, P. Lata1, R. Wanner1, M. Sudhakar1, A. Suarez1, J. Hays2, P. J. Goodfellow1, D. E. Cohn2 and S. Karuppaiyah1
1The Ohio State University Medical Center, Columbus, OH, 2The Ohio State University, James Cancer Hospital, Columbus, OH
 
7:00 AM
503
Anticancer potential of diarylidenyl piperidone derivatives, HO-4200 and HO-4318, in ovarian cancer
A. C. ElNaggar1, S. Naidu2, U. Saini2, R. Wanner2, M. Sudhakar2, D. E. Cohn1 and S. Karuppaiyah2
1The Ohio State University, James Cancer Hospital, Columbus, OH, 2The Ohio State University Medical Center, Columbus, OH
 
7:00 AM
504
The long non-coding RNA steroid receptor activator induces tumor proliferation and invasion via the Notch pathway in human ovarian cancer
H. J. Kim, K. J. Eoh, E. J. Nam, S. Kim, S. W. Kim, J. W. Kim and Y. T. Kim
Yonsei University College of Medicine, Seoul, South Korea
 
7:00 AM
506
Dual mTORC1/2 inhibitor INK128 potentiates sensitivity to carboplatin in a platinum resistant ovarian cancer cell line
G. David-West1, A. Alard2, A. Ernlund2, S. V. Blank1, J. P. Curtin1, R. Schneider1 and F. Musa1
1New York University School of Medicine, New York, NY, 2New York University Sackler Institute of Biomedical Sciences, New York, NY
 
7:00 AM
507
Progestins and vitamin D inhibit CYP24A1 in vivo in ovarian cancer cell xenografts
J. Hunn1, J. Turbov1, R. Rosales1, V. Syed2, T. P. Conrads3, K. M. Darcy3, G. L. Maxwell4, C. A. Hamilton5, L. G. Thaete1 and G. C. Rodriguez1
1Northshore University Health System, Evanston, IL, 2Uniformed Services University of the Health Sciences, Bethesda, MD, 3Gynecologic Cancer Center of Excellence, Annandale, VA, 4Inova Fairfax Hospital, Falls Church, VA, 5Walter Reed National Military Medical Center, Bethesda, MD
 
7:00 AM
508
Evaluation of ERRα expression and association with survival in advanced ovarian cancer
L. P. Cobb1, R. Whitaker2, A. Hall3, G. Broadwater3, S. K. Murphy2, A. Berchuck3 and S. Gaillard4
1Duke University School of Medicine, Durham, NC, 2Duke University, Durham, NC, 3Duke University Medical Center, Durham, NC, 4Duke Cancer Institute, Durham, NC
 
7:00 AM
509
PD-1, PD-L1 expression in 1599 gynecological cancers: implications for immunotherapy
T. J. Herzog1,2, D. Arguello3, S. K. Reddy3 and Z. Gatalica3
1University of Cincinnati Academic Health Center, Cincinnati, OH, 2University of Cincinnati, Cincinnati, OH, 3Caris Life Sciences, Irving, TX
 
7:00 AM
511
Unveiling novel mutations in the DNA-binding domain of FOXA2 in endometrioid endometrial cancers
B. Smith1, D. E. Cohn1, D. G. Mutch2, M. A. Miranda3, C. J. Walker3 and P. J. Goodfellow3
1The Ohio State University, James Cancer Hospital, Columbus, OH, 2Washington University School of Medicine, St. Louis, MO, 3The Ohio State University Medical Center, Columbus, OH
 
7:00 AM
512
Cancer testis-antigen expression shared among gynecological cancers
A. E. Garcia-Soto1, T. Koru-Sengul2, F. Miao3, W. Nieves-Neira4 and E. Podack3
1University of Miami Jackson Memorial Hospital, Miami, FL, 2University of Miami, Sylvester Cancer Center, Miami, FL, 3University of Miami Miller School of Medicine, Miami, FL, 4University of Miami Sylvester Comprehensive Cancer Center, Miami, FL
 
7:00 AM
513
Co-culture of human induced pluripotent stem cells (iPSCs) with human fallopian tube epithelium (FTE) induces Pax8 and CK7 expression: initial steps in modeling fallopian tube epithelium to study serous carcinogenesis
T. J. Vogel1, Y. Qu2, E. Suzuki2, R. Drapkin3, D. Sareen4, C. Svendsen4, X. Cui2 and B. Y. Karlan4
1Women’s Cancer Program/ Cedars-Sinai Medical Center, Los Angeles, CA, 2Womens Cancer Program/ Cedars-Sinai Medical Center, Los Angeles, CA, 3Dana-Farber Cancer Institute, Boston, MA, 4Cedars-Sinai Medical Center, Los Angeles, CA
 
7:00 AM
514
Notch receptor signaling mediates platinum and paclitaxel resistance in epithelial ovarian cancer
Y. H. Park1, J. Seoung1, H. B. Kim2, M. S. Kyung3, C. C. Rhim1 and S. Min1
1Hallym University Medical Center, Chuncheon, South Korea, 2Hallym University Sacred Heart Hospital, Seoul, South Korea, 3University of Hallym, Dongtan Sacred Heart Hospital, Hwaseong, South Korea
 
7:00 AM
515
Repurposing Artesunate, an anti-malarial, for ovarian cancer treatment: mechanistic insights from cell line models
I. Ramirez1,2, D. Marchion3, Y. Xiong3, F. Abbasi3, B. Boac2, C. McClung2, E. Al Sawah1, P. Judson2, S. M. Apte3 and J. M. Lancaster3
1University of South Florida College of Medicine, Tampa, FL, 2H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, 3H. Lee Moffitt Cancer Center, Tampa, FL
 
7:00 AM
516
Alteration of immune landscape in obesity associated endometrial hyperplasia
J. B. Pakish, M. Onstad, D. A. Iglesias, J. Celestino, Q. Zhang, R. Broaddus, M. Yates, S. Mok, R. E. Schmandt and K. H. Lu
The University of Texas MD Anderson Cancer Center, Houston, TX
 
7:00 AM
517
High-throughput matrix screening in ovarian cancer cells identifies synergistic drug combinations with the second mitochondrial-derived activator of caspases (SMAC) mimetic birinapant (TL32711)
K. P. Bunch1, I. S. Goldlust2, C. J. Thomas2 and C. M. Annunziata1
1National Cancer Institute, Bethesda, MD, 2National Center for Advancing Translational Sciences, Rockville, MD
 
7:00 AM
518
Small molecule activators of protein phosphatase 2A for the treatment of endometrial cancer
S. Singh1, P. Joseph2, A. B. Nagaraj2, A. Armstrong1, K. E. Resnick1, K. M. Zanotti1, S. E. Waggoner1, G. Narla2 and A. DiFeo2
1University Hospitals Case Medical Center, Cleveland, OH, 2Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH
 
7:00 AM
519
Biomarker comparison of epithelial ovarian cancer and endometrial cancer by multiplatform tumor profiling
H. Mahdi1, J. Xiu2, S. K. Reddy2 and R. DeBernardo1
1Cleveland Clinic, Cleveland, OH, 2Caris Life Sciences, Irving, TX
 
7:00 AM
520
Investigating the role of phosphodiesterase 10A as a novel target in ovarian cancer
L. M. da Silva, K. Lee, G. Piazza, L. Bachaboina, R. P. Rocconi and J. M. Scalici
University of South Alabama-Mitchell Cancer Institute, Mobile, AL
 
7:00 AM
521
Ovarian cancer screening in high risk menopausal females
T. Lai, H. J. Ahn, J. Elia and K. Y. Terada
University of Hawaii at Manoa, Honolulu, HI
 
See more of: Poster Session
<< Previous Course | Next Course >>